-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Recently, the Heilongjiang Drug Centralized Purchasing Network issued the "Notice on the Price Reduction of Some Drugs.
The notice shows that Beijing Ruiye Pharmaceutical C.
, Lt.
and other companies actively applied for price reduction, and the new price will be implemented from August 13, 2021.Among them, it can be seen from the price reduction information table of some medicines that many proprietary Chinese medicines have taken the initiative to reduce the pric.
For example, the original price of Liuwei Dihuang Pills (film-coated pills) of 3 grams per bag (film-coated pills) was 866 yua.
In the notice, Hulun Buir Songlu Pharmaceutical C.
, Lt.
has adjusted the product price to 166 yuan per box; Songlu Pharmaceutical's Xihuang Pills (cultivating bezoar) have also reduced the price by an astonishing amoun.
The price is 995 yuan, and the price is 95 yuan after price adjustmen.
The price cuts of both drugs are as high as 90.
In fact, it is not uncommon for the price reduction of Chinese patent medicines this yea.
Since August, the results of the centralized procurement of Chinese patent medicines led by Hubei Province have been selected in many place.
Affected by this, a large number of Chinese patent medicines in many provinces and cities have also Started to usher in a "price drop.
For example, starting from August 8, the results of the centralized procurement of the provincial alliance of Chinese patent medicines will be implemented in all public medical institutions in Quanzhou and the medical institutions of the troops stationed in Quanzho.
Comprehensive price reduction, the highest drop can reach 863.
The implementation of the inter-provincial alliance of Chinese patent medicines with volume and centralized procurement marks the expansion of the scope of centralized drug procurement from Western medicine to the field of Chinese patent medicines, and is an important milestone in the reform of centralized drug procuremen.
The centralized procurement of Chinese patent medicines covers 76 drug varieties in 17 product groups, including common varieties of Chinese patent medicines such as Xuesaitong, Xueshuantong, and Kangfuxin Liqui.
Among them, the price of a certain brand of ginkgo leaves per box (30 pieces) for the treatment of stroke dropped from 24 yuan to 17 yuan, a drop of 863%, and the price of a certain brand of Shuanghuanglian oral liquid per box (12 pieces) dropped from 25 yuan to 125 yuan Yuan, a drop of 55.
According to statistics, after the implementation of the results of the centralized procurement of proprietary Chinese medicines, it is expected that Quanzhou will save 24 million yuan in drug procurement funds a year, effectively reducing the burden of medical expenses on the masse.
Recently, under the active promotion of the Municipal Medical Security Bureau, the results of the first batch of Chinese patent medicine inter-provincial alliance centralized procurement have also been implemented in Suining Cit.
At present, 90 public hospitals in Suining have signed the first batch of contracts for the centralized procurement of proprietary Chinese medicines, with a total amount of 0246 million yuan, which is expected to reduce the city's patients' medical burden by more than 3 million yua.
From the perspective of the industry, the centralized procurement of proprietary Chinese medicines has become the general tren.
In this context, the "price reduction tide" will also arise in the industr.
Under the new situation, the transformation and upgrading of the Chinese patent medicine industry is imperativ.
In fact, in recent years, it can be clearly seen that a large number of traditional Chinese patent medicine companies have been under pressure from the impact of pharmaceutical policies, and have gradually expanded their business scope to other fields, including non-pharmaceutical fields such as daily chemicals and beverages, as well as related field.
Medicine-related medical equipment, medical beauty and other track.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
The notice shows that Beijing Ruiye Pharmaceutical C.
, Lt.
and other companies actively applied for price reduction, and the new price will be implemented from August 13, 2021.Among them, it can be seen from the price reduction information table of some medicines that many proprietary Chinese medicines have taken the initiative to reduce the pric.
For example, the original price of Liuwei Dihuang Pills (film-coated pills) of 3 grams per bag (film-coated pills) was 866 yua.
In the notice, Hulun Buir Songlu Pharmaceutical C.
, Lt.
has adjusted the product price to 166 yuan per box; Songlu Pharmaceutical's Xihuang Pills (cultivating bezoar) have also reduced the price by an astonishing amoun.
The price is 995 yuan, and the price is 95 yuan after price adjustmen.
The price cuts of both drugs are as high as 90.
In fact, it is not uncommon for the price reduction of Chinese patent medicines this yea.
Since August, the results of the centralized procurement of Chinese patent medicines led by Hubei Province have been selected in many place.
Affected by this, a large number of Chinese patent medicines in many provinces and cities have also Started to usher in a "price drop.
For example, starting from August 8, the results of the centralized procurement of the provincial alliance of Chinese patent medicines will be implemented in all public medical institutions in Quanzhou and the medical institutions of the troops stationed in Quanzho.
Comprehensive price reduction, the highest drop can reach 863.
The implementation of the inter-provincial alliance of Chinese patent medicines with volume and centralized procurement marks the expansion of the scope of centralized drug procurement from Western medicine to the field of Chinese patent medicines, and is an important milestone in the reform of centralized drug procuremen.
The centralized procurement of Chinese patent medicines covers 76 drug varieties in 17 product groups, including common varieties of Chinese patent medicines such as Xuesaitong, Xueshuantong, and Kangfuxin Liqui.
Among them, the price of a certain brand of ginkgo leaves per box (30 pieces) for the treatment of stroke dropped from 24 yuan to 17 yuan, a drop of 863%, and the price of a certain brand of Shuanghuanglian oral liquid per box (12 pieces) dropped from 25 yuan to 125 yuan Yuan, a drop of 55.
According to statistics, after the implementation of the results of the centralized procurement of proprietary Chinese medicines, it is expected that Quanzhou will save 24 million yuan in drug procurement funds a year, effectively reducing the burden of medical expenses on the masse.
Recently, under the active promotion of the Municipal Medical Security Bureau, the results of the first batch of Chinese patent medicine inter-provincial alliance centralized procurement have also been implemented in Suining Cit.
At present, 90 public hospitals in Suining have signed the first batch of contracts for the centralized procurement of proprietary Chinese medicines, with a total amount of 0246 million yuan, which is expected to reduce the city's patients' medical burden by more than 3 million yua.
From the perspective of the industry, the centralized procurement of proprietary Chinese medicines has become the general tren.
In this context, the "price reduction tide" will also arise in the industr.
Under the new situation, the transformation and upgrading of the Chinese patent medicine industry is imperativ.
In fact, in recent years, it can be clearly seen that a large number of traditional Chinese patent medicine companies have been under pressure from the impact of pharmaceutical policies, and have gradually expanded their business scope to other fields, including non-pharmaceutical fields such as daily chemicals and beverages, as well as related field.
Medicine-related medical equipment, medical beauty and other track.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
